Kiran Fida

Ms. Kiran Fida


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MHMohammed Tanveer Hussain
Mohammed Tanveer Hussain
KFKiran Fida
Kiran Fida
AAAmber A. Anderson
Amber A. Anderson
MRMd. Mostafijur Rahman
Md. Mostafijur Rahman
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
Brent A. StanfieldBrent A. Stanfield
Brent A. Stanfield
Cervical cancer is a major cause of mortality worldwide and has been attributed to long-lasting (persistent) infections with the human papillomavirus (HPV). Although more than 50 types of HPVs are known the infect the genital tract, fewer than a dozen of them are regularly linked to cervical cancers leading to these types being designated as “high risk” HPVs. Worldwide, over 90% of cervical cancers arise from persistent high-risk human papillomavirus (HPV) infection and the infectious nature of the virus procures the need for preventative vaccines against cervical cancer. To address this, we have developed a live-attenuated herpes simplex virus type 1 (HSV-1) VC2-vectored vaccine expressing a catalytically inactive mutant of HPV-16 E7 (E7m) fused to the viral capsid protein VP26. Incorporation of E7m into the VC2 backbone resulted in stable incorporation of VP26-E7m fusion protein in cell free viral particles and detectable intracellular expression within infected cells. The recombinant virus (E7m VC-2) maintained growth kinetics comparable to parental VC2 in vitro, though plaque size was modestly reduced, suggesting a minimal fitness cost associated with transgene insertion. To evaluate prophylactic efficacy, mice received a one-dose vaccine schedule of E7m VC-2 prior to challenge with syngeneic HPV-16 E6/E7-expressing tumor cells. In mice that did develop tumors, growth kinetics were attenuated relative to unvaccinated animals. Importantly, neither E7m VC-2 nor adjuvanted E7m protein alone achieved statistically significant protection versus untreated controls. Immunohistochemical analysis of tumor tissue revealed markedly increased CD8+ T cell infiltration in E7m VC-2 vaccinated mice, demonstrating that vaccination promotes a cytotoxic immune microenvironment capable of restricting tumor progression. Three-dose vaccination of mice with E7m VC-2 induced a robust Th1-polarized immune response characterized by strong interferon-gamma (IFN-γ) secretion in response to HPV16 E7 expressing syngeneic cell lines, consistent with the induction of cell-mediated antitumor immunity and superior to responses elicited by adjuvanted E7m protein alone. With an extended three-dose vaccination schedule E7m VC-2 conferred significantly greater protection against tumor establishment relative to untreated controls (80% vs. 20% tumor-free). Collectively, these findings establish proof-of-concept for the HSV-1 VC2 platform as an effective vector for HPV-targeted cancer immunotherapy, delivering statistically significant prophylactic protection alongside potent induction of tumor-reactive CD8+ T cells. Future studies will incorporate both E6 and E7 antigens to broaden antigenic coverage, evaluate therapeutic efficacy in established tumor models, and optimize dosing regimens with the long-term goal of advancing this Louisiana-developed platform toward IND-enabling studies and clinical translation.